744 860
[12]
Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adju- vant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243–52.[13]
Beckendorf V, Guerif S, Le Prise´ E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011;80:1056–63.[14]
Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475–87.
[15]
Kuban DA, Tucker SL, Dong L, et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
[16]
Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106–11.
[17]
Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radio- therapy with 78 Gy. J Clin Oncol 2006;24:1990–6.
[18]
Heemsbergen WD, Al-Mamgani A, Slot A, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose- escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 2014;110:104–9.
[19]
Hoskin PJ, Rojas AM, Bownes PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachy- therapy boost for localised prostate cancer. Radiother Oncol 2012;103:217–22.[20]
Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23:1192–9.
[21]
Morris WJ, Tyldesley S, Pai HH, et al. ASCENDE-RT*: a multicenter, randomized trial of dose-escalated external beam radiation thera- py (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J Clin Oncol 2015;33(Suppl 7):3.
[22]
Bilimoria KY, Stewart AK, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683–90.[23]
Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. J Natl Compr Cancer Netw 2016;14:19–30.
[24]
Charlson M, Szatrowski TP, Peterson J, et al. Validation of a com- bined comorbidity index. J Clin Epidemiol 1994;47:1245–51.
[25]
Amini A, Jones B, Jackson MW, et al. Survival outcomes of dose- escalated external beam radiotherapy versus combined brachy- therapy for intermediate and high risk prostate cancer using the National Cancer Data Base. J Urol 2016;195:1453–8.[26]
Lin CC, Virgo KS, Robbins AS, et al. Comparison of comorbid medical conditions in the National Cancer Database and the SEER–Medicare database. Ann Surg Oncol 2016;23:4139–48.[27]
Keane FK, Chen MH, Zhang D, et al. The likelihood of death from prostate cancer inmen with favorable or unfavorable intermediate- risk disease. Cancer 2014;120:1787–93.
[28]
Muralidhar V, Xiang M, O rio III PF, et al. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high- risk prostate cancer. J Contemp Brachyther 2016;8:1.[29]
Martin JM, Handorf EA, Kutikov A, et al. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer 2014;120:2114–21.
[30]
Mitchell JM. Urologists’ use of intensity-modulated radiation ther- apy for prostate cancer. N Engl J Med 2013;369:1629–37.
[31]
Compton JJ, Gaspar LE, Shrieve DC, et al. Resident-reported brachy- therapy experience in ACGME-accredited radiation oncology train- ing programs. Brachytherapy 2013;12:622–7.[32]
Petereit DG, Frank SJ, Viswanathan AN, et al. Brachytherapy: where has it gone? J Clin Oncol 2015;33:980–2.
[33]
Rodda S, Duncan G, Hamm J, et al. Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2015;3:S2.
[34]
Chen Y-W, Muralidhar V, Mahal BA, et al. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy 2016;15:695–700.
[35]
Lawton CA, DeSilvio M, Roach M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69:646–55.
[36]
Pommier P, Chabaud S, Lagrange J-L, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 2016;96:759–69.
[37]
Giordano SH, Kuo YF, Duan Z, et al. Limits of observational data in determining outcomes from cancer therapy. Cancer 2008;112: 2456–66.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 7 3 8 – 7 4 4
744